Finland's Nanoform Q2 EBITDA loss narrows on layoffs, cost cuts

Nanoform Finland Oyj

20/08/2026 06:18

Overview
Finland medicine performance-enhancer's Q2 revenue grew 16% yr/yr, adjusted EPS loss narrowed
Company's Q2 EBITDA loss narrowed as operating costs fell 36% yr/yr
Nanoform continued cost-saving measures, including layoffs and reduced headcount

Outlook
Nanoform targets 2026 cash burn below EUR 10 mln
Company expects to submit first market authorization application for nanoenzalutamide before end-2026
Nanoform aims to increase number of non-GMP and GMP projects signed in 2026 vs 2025

Result Drivers
COST REDUCTIONS - Co said lower operating costs were driven by layoffs and part-time layoffs implemented earlier in the year
REGULATORY PROGRESS - Co said positive feedback from UK MHRA supports a potentially faster, less expensive approval route for nanoenzalutamide
NEW BUSINESS AGREEMENT - Co signed exclusivity deal with U.S. biopharma partner for biologics nanoparticle technology

Company press release: ID:nMFN7B3rBB

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
EUR 800,000
 
Q2 Gross Margin
 
84.00%
 
Q2 EBITDA
 
-EUR 3 mln
 
Q2 Gross Profit
 
EUR 700,000
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Nanoform Finland Oyj is €2.13, about 121.1% above its August 19 closing price of €0.96

Reuters Recommended Reads
Aug 19 - Sino Biopharmaceutical H1 revenue up 10.6% on innovative drug sales
Aug 19 - Denmark's Lundbeck Q2 revenue rises 7% driven by Vyepti and Rexulti
Aug 19 - UK's Oxford Nanopore H1 revenue rises on clinical, biopharma segements growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)